Megan Stallworth

Cooley advised LFX Venture Partners, a knowledge-based investor focusing on first, middle, and last-mile cutting-edge technologies and disruptive business models that drive innovation in the global value chain, on its investment in Pipe17’s $15.5 million Series A financing round. Partner Sale Kwon led the Cooley team advising LFX Venture Partners.

Cooley advised Samsung Venture Investment Corporation – the corporate venture capital arm of Samsung Group, based in Seoul, South Korea – on its investment in Pison Technology. Partner Sale Kwon led the Cooley team advising Samsung Venture Investment Corporation, which frequently invests in technology companies in various sectors, including the semiconductor, telecommunications, software, internet, bioengineering and medical sectors, across Europe, Asia and North America.

Cooley advised Arsenal Biosciences (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors, on the close of its oversubscribed $325 million Series C financing round.

Cooley advised New Enterprise Associates (NEA), a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. as the lead investor in Brenig Therapeutics’ $65 million Series A financing. Brenig is a pioneering neurology-focused drug development company utilizing an artificial intelligence/machine learning (AI/ML)-based discovery platform for the treatment of Parkinson’s disease. Partner Josh Seidenfeld led the Cooley team advising NEA.

Cooley advised Vaxcyte, a clinical-stage vaccine innovation company, on its $862.5 million follow-on public offering.